Terms: = Skin cancer AND CD52, CDW52, EDDM5 AND Treatment
16 results:
1. cd52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract] [Full Text] [Related]
2. Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas.
Sugaya M
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681738
[TBL] [Abstract] [Full Text] [Related]
3. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
Van-de-Velde V; Zhou Y
J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
[TBL] [Abstract] [Full Text] [Related]
4. Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment.
Cerroni L
Semin Cutan Med Surg; 2018 Mar; 37(1):2-10. PubMed ID: 29719014
[TBL] [Abstract] [Full Text] [Related]
5. Monoclonal antibodies against cutaneous T-cell lymphomas.
Alaibac M
Expert Opin Biol Ther; 2017 Dec; 17(12):1503-1510. PubMed ID: 28829215
[TBL] [Abstract] [Full Text] [Related]
6. Alemtuzumab in refractory Sézary syndrome.
Reifs CM; Salido-Vallejo R; Garnacho-Saucedo GM; Corte-Sánchez S; González-Menchen A; García-Nieto AV
An Bras Dermatol; 2016; 91(5):642-644. PubMed ID: 27828640
[TBL] [Abstract] [Full Text] [Related]
7. Histopathologic spectrum of hypersensitivity reactions associated with anti-cd52 therapy (alemtuzumab).
Clark SL; Tse JY; Fisher DC; LeBeouf NR; Murphy GF; Kupper TS; Clark RA; Lian CG
J Cutan Pathol; 2016 Nov; 43(11):989-993. PubMed ID: 27531597
[TBL] [Abstract] [Full Text] [Related]
8. Alemtuzumab treatment for Sézary syndrome: A single-center experience.
Novelli S; García-Muret P; Sierra J; Briones J
J Dermatolog Treat; 2016; 27(2):179-81. PubMed ID: 26329989
[TBL] [Abstract] [Full Text] [Related]
9. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.
Hasanali ZS; Saroya BS; Stuart A; Shimko S; Evans J; Vinod Shah M; Sharma K; Leshchenko VV; Parekh S; Loughran TP; Epner EM
Sci Transl Med; 2015 Jun; 7(293):293ra102. PubMed ID: 26109102
[TBL] [Abstract] [Full Text] [Related]
10. Incidence and risk of xerosis with targeted anticancer therapies.
Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
J Am Acad Dermatol; 2015 Apr; 72(4):656-67. PubMed ID: 25637330
[TBL] [Abstract] [Full Text] [Related]
11. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
Boyd K; Dearden CE
Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
[TBL] [Abstract] [Full Text] [Related]
12. Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome.
Roch N; Salameire D; Gressin R; Morand P; Epaulard O; Pavese P; Brion JP; Stahl JP
Scand J Infect Dis; 2008; 40(4):343-6. PubMed ID: 17934981
[TBL] [Abstract] [Full Text] [Related]
13. [Cutaneous lymphomas].
Bachelez H
Rev Prat; 2007 Mar; 57(5):469-75. PubMed ID: 17583131
[TBL] [Abstract] [Full Text] [Related]
14. Drug therapy for the treatment of Langerhans cell histiocytosis.
McClain KL
Expert Opin Pharmacother; 2005 Nov; 6(14):2435-41. PubMed ID: 16259575
[TBL] [Abstract] [Full Text] [Related]
15. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
[TBL] [Abstract] [Full Text] [Related]
16. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
Keating MJ; Cazin B; Coutré S; Birhiray R; Kovacsovics T; Langer W; Leber B; Maughan T; Rai K; Tjønnfjord G; Bekradda M; Itzhaki M; Hérait P
J Clin Oncol; 2002 Jan; 20(1):205-13. PubMed ID: 11773171
[TBL] [Abstract] [Full Text] [Related]
